摘要
目的探讨黄芪-莪术药对文献规律及其在抗肿瘤研究中的作用机理。方法利用中国知网数据库检索黄芪-莪术药对相关文献,并进行在线可视化分析与剂量配比研究。利用TCMSP和Uniprot网站筛选黄芪-莪术药对作用靶点,与多种肿瘤及炎症相关基因集交集,进而利用String数据库对“药对-肿瘤-炎症”三者交集靶点的富集通路进行分析。结果黄芪-莪术药对相关文献量成逐年上升趋势,2005年是文献量增长的重要拐点。肿瘤学领域是该药对研究的重要领域,其中肺癌、乳腺癌、肝癌、胃癌、结肠癌和卵巢癌研究均有报导。发文量最多的机构和作者分别是南京中医药大学(64篇)与唐德才(31篇)。黄芪-莪术药对抗肿瘤文献中剂量配比主要分布在1∶1(34.9%)、2∶1(30.2%)、3∶1(9.3%)这三种比例。黄芪-莪术药对作用靶点与上述6种肿瘤以及炎症基因集共有240个交集作用靶点。这些靶点在Pathways in cancer(70个)、PI3K-AKT signaling pathway(40个)、MAPK signaling pathway(36个)和Fluid shear stress and atherosclerosis(35个)为代表的KEGG通路是富集。结论黄芪-莪术药对具有广谱抗肿瘤作用,并可能通过调节炎症的方式截断“炎癌转变”和发挥“异病同治”的作用。
Objective To explore the literature and mechanism of Huangqi-Ezhu in anti-tumor research.Methods Using the China National Knowledge Infrastructure database to search for relevant literature on Huangqi-Ezhu,and conducting online visualization analysis and dose ratio research.Using TCMSP and Uniprot websites to screen the targets of Huangqi-Ezhu,intersect with various tumor and inflammation related genes,and then analyze the enrichment pathway of the intersection targets of"drugs-tumor-inflammation"using the String database.Results The number of related literatures on Huangqi-Ezhu has been increasing year by year,and 2005 was an important turning point for the growth of literature.Oncology is an important field in the research of Huangqi-Ezhu,including lung cancer,breast cancer,liver cancer,stomach cancer,colon cancer and ovarian cancer.The institutions and authors with the highest volume of publications are Nanjing University of Traditional Chinese Medicine(64 articles)and Tang Decai(31 articles).The dosage ratio of Huangqi-Ezhu in anti-tumor literature is mainly distributed in three proportions:1∶1(30%),2∶1(40%),and 3∶1(30%).The number of intersection targets of"drugs-tumor-inflammation"is 240.These targets are enriched in the KEGG pathway represented by Pathways in cancer(70),PI3K-Akt signaling pathway(40),MAPK signaling pathway(36),and Fluid shear stress and aerosclerosis(35).Conclusions Huangqi-Ezhu has a spectral anti-tumor effect and may intercept the"inflammation and cancer transformation"and play a role in"same treatment for different disease"by regulating inflammation.
作者
赵一鸣
徐曼曼
李杰
ZHAO Yiming;XU Manman;LI Jie(Guang'anmen Hospital,Chinese Academy of Traditional Chinese Medicine,Beijing 100032,China)
出处
《实用中医内科杂志》
2025年第1期42-48,I0014-I0016,共10页
Journal of Practical Traditional Chinese Internal Medicine
基金
国家自然科学基金青年基金项目(82204922)
中央高水平中医医院临床研究和成果转化能力提升项目-临床科研一体化人才专项(创新团队培育项目)(HLCMHPP2023001)
中央高水平中医医院临床研究和成果转化能力提升项目-临床科研一体化人才专项(CZ40904)
北京市重大疑难疾病中西医协同攻关项目(2023BJSZDYNJBXTGG-013)。
关键词
黄芪
莪术
药对
剂量
异病同治
Ezhu
Huangqi
drug pairing
dosage ratio
same treatment for different disease
作者简介
赵一鸣(1994-),女,山东淄博人,医师,硕士,研究方向:中西医结合肿瘤;通讯作者:李杰(1971-),男,河北保定人,主任医师,博士,研究方向:中西医结合肿瘤。E-mail:qfm2020jieli@yeah.net。
